Event

Lecture Series: Digital Health and Digital Biomarkers – Digital Biomarkers in Clinical Trails: Boon or Bane?

  • Conférencier  Dr Thanneer Malai Perumal

  • Lieu

    Biotech II (BT2) – RIKEN room

    6, avenue du Swing

    L-5367, Belvaux, LU

In-person or Join via WebEx.

Digital biomarkers (dBM), frequent measurements of clinically relevant signals and functioning using sensors in individuals’ daily lives to quantify their disease trajectories, can significantly impact drug development. However, only very few have contributed meaningfully in the past few years. Do these developments really warrant a business case? This talk will present the steps involved in successfully developing dBM with a case study. It will highlight the various values and impacts dBM can generate to bring novel treatments faster and cheaper to the market. This talk will also highlight some of the common barriers that the industry currently encounters and will provide you with an outlook.

Dr Thanneer Malai Perumal is a digital measurements scientist working at the intersection of technology, clinical research, and healthcare to understand the needs and experiences of people living with diseases. By combining science and strategy, he currently drives the vision, strategy, and roadmap to develop novel digital outcome measures for Alzheimer’s disease and Relevant Dementia, Parkinson’s disease, and Neuromuscular disorders. He received his PhD in Chemical & Biomolecular Engineering from the University of Singapore in 2011. After working on the Parkinson’s Disease Map at the LCSB from 2012 to 2014, he worked as Senior Research Scientist at Sage Bionetworks in Seattle. Now he is the Principal Scientist of Digital Biomarker Technology at Roche in Switzerland.

This lecture series is organised jointly by the Luxembourg Centre of Systems Biomedicine (LCSB) at the University of Luxembourg and the Luxembourg Institute of Health (LIH) with financial support from the National Research Fund (FNR).